Physician profile
Taylor Lyon
NPI 1942825773
$5,682.45
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,645 · 2022: $3,038.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,695.91 | 2022 | |
| Novo Nordisk INC | $661.07 | 2021-2022 | |
| Esperion Therapeutics, INC. | $659.29 | 2021-2022 | |
| Amgen INC. | $580.15 | 2021-2022 | |
| Abbvie INC. | $550.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $254.79 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.69 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $142.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $119.47 | 2021 | |
| Lilly USA, LLC | $100.88 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $98.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.44 | 2021 | |
| Radius Health, INC. | $69.49 | 2021 | |
| Eisai INC. | $66.89 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $63.01 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $57.43 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.61 | 2022 | |
| Glaxosmithkline, LLC. | $43.94 | 2021-2022 | |
| Advanced Respiratory, INC | $42.41 | 2021 | |
| Pfizer INC. | $42.25 | 2021-2022 | |
| Abbott Laboratories | $27.76 | 2022 | |
| Si-Bone, INC. | $24.48 | 2022 | |
| Smith+Nephew, INC. | $20.71 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2021 | |
| Currax Pharmaceuticals LLC | $16.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.76 | 2021 | |
| Nevro Corp. | $15.30 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Lyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.